Twinn Health, a British health tech startup backed by a $500 million venture capital fund from Saudi Aramco, has developed an AI platform that uses imaging biomarkers to analyze MRI scans for early disease detection. The platform aims to improve decision-making in disease diagnosis and treatment, and the company is making strides in longevity and preventive healthcare.

Twinn Health's patented AI model can foresee metabolic dysfunction up to half a decade ahead of time, and early trials have shown promising results with a 95% accuracy rate in 2021. The company is seeking additional funding as it expands its reach into multiple disease pathways.